A citation-based method for searching scientific literature

Laura M Spring, Geoffrey Fell, Andrea Arfe, Chandni Sharma, Rachel Greenup, Kerry L Reynolds, Barbara L Smith, Brian Alexander, Beverly Moy, Steven J Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia. Clin Cancer Res 2020
Times Cited: 106







List of co-cited articles
572 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
52

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
737
30

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
590
30


Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
508
22

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
20

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
19

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
822
18

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
297
17

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Sinn,[...]. J Clin Oncol 2017
268
14

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
526
14

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A Jo Chien, Andres Forero-Torres, Erin Ellis, Heather Han,[...]. JAMA Oncol 2020
179
12


Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Michael Untch, Christian Jackisch, Andreas Schneeweiss, Bettina Conrad, Bahriye Aktas, Carsten Denkert, Holger Eidtmann, Hermann Wiebringhaus, Sherko Kümmel, Jörn Hilfrich,[...]. Lancet Oncol 2016
204
11

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, Jan Bogaerts, Leen Slaets, Giuseppe Viale, Suzette Delaloge, Jean-Yves Pierga, Etienne Brain, Sylvain Causeret, Mauro DeLorenzi,[...]. N Engl J Med 2016
862
10

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
10

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
517
10

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
9

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys. Breast 2003
498
9

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren,[...]. Lancet 2012
870
9

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Ana Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vazquez, Mikhail J Byakhov, Mikhail Lichinitser,[...]. Lancet Oncol 2014
273
9

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Kristine R Broglio, Melanie Quintana, Margaret Foster, Melissa Olinger, Anna McGlothlin, Scott M Berry, Jean-François Boileau, Christine Brezden-Masley, Stephen Chia, Susan Dent,[...]. JAMA Oncol 2016
135
9

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
681
8

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Lisa A Carey, Donald A Berry, Constance T Cirrincione, William T Barry, Brandelyn N Pitcher, Lyndsay N Harris, David W Ollila, Ian E Krop, Norah Lynn Henry, Douglas J Weckstein,[...]. J Clin Oncol 2016
220
8

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
866
8

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Starosławska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini,[...]. Lancet Oncol 2016
360
8

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper, Vincent O Dezentjé, Irma M Oving, Aafke H Honkoop, Lidwine W Tick, Agnes J van de Wouw,[...]. Lancet Oncol 2018
94
8

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, Shannon E McKernin, Lisa A Carey, Patrick L Fitzgibbons, Daniel F Hayes, Sunil R Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter,[...]. J Clin Oncol 2020
207
8

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli,[...]. Lancet 2020
195
8

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini. Ann Oncol 2018
143
8

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
8

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
7

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
7

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark,[...]. N Engl J Med 2017
615
7

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
779
7

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Nehmat Houssami, Petra Macaskill, Gunter von Minckwitz, Michael L Marinovich, Eleftherios Mamounas. Eur J Cancer 2012
281
7

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997
7

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
658
7

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005
746
7

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.
Sarah S Mougalian, Pamela R Soulos, Brigid K Killelea, Donald R Lannin, Maysa M Abu-Khalaf, Michael P DiGiovanna, Tara B Sanft, Lajos Pusztai, Cary P Gross, Anees B Chagpar. Cancer 2015
111
7

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, M Colleoni, C Denkert, M Piccart-Gebhart, M Regan,[...]. Ann Oncol 2019
258
7

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
7

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun,[...]. Ann Oncol 2018
114
7

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
Douglas Yee, Angela M DeMichele, Christina Yau, Claudine Isaacs, W Fraser Symmans, Kathy S Albain, Yunn-Yi Chen, Gregor Krings, Shi Wei, Shuko Harada,[...]. JAMA Oncol 2020
35
20

Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki,[...]. N Engl J Med 2011
7

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria,[...]. J Clin Oncol 2019
268
6


Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Carsten Denkert, Gunter von Minckwitz, Jan C Brase, Bruno V Sinn, Stephan Gade, Ralf Kronenwett, Berit M Pfitzner, Christoph Salat, Sherene Loi, Wolfgang D Schmitt,[...]. J Clin Oncol 2015
603
6

Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, Maggie C U Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu,[...]. J Clin Oncol 2009
6

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
598
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.